4th Quarter - Report

COVINGTON & BURLING LLP for PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC

Firm
Client
Income
$170,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843).

LobbyistCovered position, as disclosed
KRISTA CARVER —
MICHAEL STERN —

Bills named: H.R. 1843 (119th), H.R. 6485 (119th), S. 1302 (119th), S. 43 (119th)

Health Issues HCR

FDA Modernization Act 3.0 (S. 355 / H.R. 2821); Expedited Access to Biosimilars Act (S. 1414); Orphan-drug exclusivity; draft Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act (no bill number); Clinical Trials; Reciprocal approvals; Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843); BIOSECURE Act, Sec. 851 of the Fiscal Year (FY) 2026 National Defense Authorization Act (NDAA)(S. 1071/H.R. 3838); Potential legislation relating to the Vaccine Injury Compensation Program and other issues affecting vaccines.

LobbyistCovered position, as disclosed
KRISTA CARVER —
RICHARD F KINGHAM —
JENNIFER L PLITSCH —
MICHAEL STERN —

Bills named: S. 355 (119th), H.R. 1843 (119th), H.R. 6485 (119th), S. 1071 (119th), S. 1302 (119th), H.R. 3838 (119th), S. 43 (119th), H.R. 2821 (119th), S. 1414 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.